The estimated Net Worth of Timothy Eugene Sullivan is at least $5.99 Million dollars as of 1 April 2024. Mr. Sullivan owns over 4,000 units of Apellis Pharmaceuticals Inc stock worth over $3,733,886 and over the last 5 years he sold APLS stock worth over $535,225. In addition, he makes $1,719,300 as Chief Financial Officer and Treasurer at Apellis Pharmaceuticals Inc.
Timothy has made over 11 trades of the Apellis Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of APLS stock worth $40,120 on 1 April 2024.
The largest trade he's ever made was exercising 69,779 units of Apellis Pharmaceuticals Inc stock on 5 June 2023 worth over $699,883. On average, Timothy trades about 6,417 units every 67 days since 2019. As of 1 April 2024 he still owns at least 97,338 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Mr. Sullivan stock trades at the bottom of the page.
Timothy Sullivan is Chief Financial Officer, Treasurer of the Company. From January 2014 to October 2017, Mr. Sullivan served as Partner at Solasta Ventures (formerly known as AJU IB Investment), a venture capital firm, at which he led the firm’s investments in life sciences companies. Prior to joining Solasta Ventures, from December 2011 to January 2014, Mr. Sullivan was Managing Director, Head of Life Sciences at RBS Citizens. Mr. Sullivan was an observer on our board of directors from November 2014 until October 2017. Mr. Sullivan has previously served as a director of G1 Therapeutics, Inc. and Molecular Templates, Inc. Mr. Sullivan received his M.B.A. from the Columbia Business School and his B.A. in Biology from Harvard University.
As the Chief Financial Officer and Treasurer of Apellis Pharmaceuticals Inc, the total compensation of Timothy Sullivan at Apellis Pharmaceuticals Inc is $1,719,300. There are 5 executives at Apellis Pharmaceuticals Inc getting paid more, with Cedric Francois having the highest compensation of $4,267,180.
Timothy Sullivan is 49, he's been the Chief Financial Officer and Treasurer of Apellis Pharmaceuticals Inc since 2017. There are 9 older and 11 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
Timothy's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, and Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: